|An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK.|
|PMID: 23145499 Owner: NLM Status: MEDLINE|
|BACKGROUND AND PURPOSE: Oltipraz, a cancer chemopreventive agent, has an anti-steatotic effect via liver X receptor-α (LXRα) inhibition. Here we have assessed the biological activity of a major metabolite of oltipraz (M2) against liver steatosis and steatohepatitis and the underlying mechanism(s).
EXPERIMENTAL APPROACH: Blood biochemistry and histopathology were assessed in high-fat diet (HFD)-fed mice treated with M2. An in vitroHepG2 cell model was used to study the mechanism of action. Immunoblotting, real-time PCR and luciferase reporter assays were performed to measure target protein or gene expression levels.
KEY RESULTS: M2 treatment inhibited HFD-induced steatohepatitis and diminished oxidative stress in liver. It increased expression of genes encoding proteins involved in mitochondrial fuel oxidation. Mitochondrial DNA content and oxygen consumption rate were enhanced. Moreover, M2 treatment repressed activity of LXRα and induction of its target genes, indicating anti-lipogenic effects. M2 activated AMP-activated protein kinase (AMPK). Inhibition of AMPK by over-expression of dominant negative AMPK (DN-AMPK) or by Compound C prevented M2 from inducing genes for fatty acid oxidation and repressed sterol regulatory element binding protein-1c (SREBP-1c) expression. M2 activated liver kinase B1 (LKB1) and increased the AMP/ATP ratio. LKB1 knockdown failed to reverse target protein modulations or AMPK activation by M2, supporting the proposal that both LKB1 and increased AMP/ATP ratio contribute to its anti-steatotic effect.
CONCLUSION AND IMPLICATIONS: M2 inhibited liver steatosis and steatohepatitis by enhancing mitochondrial fuel oxidation and inhibiting lipogenesis. These effects reflected activation of AMPK elicited by increases in LKB1 activity and AMP/ATP ratio.
|Tae Hyun Kim; Jeong Sik Eom; Chan Gyu Lee; Yoon Mee Yang; Yong Sup Lee; Sang Geon Kim|
Related Documents :
|11306069 - Identification and expression of cosmids with an allelic variant of class i alcohol deh...
8432399 - Expression of chimeric human transferrin-chloramphenicol acetyltransferase genes in liv...
3181649 - A mouse minialbumin gene is specifically expressed in differentiated hepatoma cells but...
10498879 - Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector.
9016659 - Variegated expression of a globin transgene correlates with chromatin accessibility but...
17203649 - Conditional somatic mutagenesis in the mouse using site-specific recombinases.
11702059 - Analysis of tumor necrosis factor-alpha gene promoter polymorphisms in anorexia nervosa.
9025309 - Development of a simple transient assay for ac/ds activity in cells of intact barley ti...
11352569 - Characterization of the human ndrg gene family: a newly identified member, ndrg4, is sp...
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: British journal of pharmacology Volume: 168 ISSN: 1476-5381 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2013 Apr|
|Created Date: 2013-03-15 Completed Date: 2013-11-25 Revised Date: 2014-04-01|
Medline Journal Info:
|Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England|
|Languages: eng Pagination: 1647-61 Citation Subset: IM|
|© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.|
|APA/MLA Format Download EndNote Download BibTex|
AMP-Activated Protein Kinases
Anti-Inflammatory Agents / pharmacology*
Anticarcinogenic Agents / metabolism, pharmacology
Antioxidants / pharmacology*
Fatty Liver / drug therapy, metabolism, pathology
Hep G2 Cells
Lipid Metabolism / drug effects
Lipogenesis / drug effects*
Liver / drug effects*, metabolism
Mice, Inbred C57BL
Mitochondria / drug effects*, metabolism
Orphan Nuclear Receptors / antagonists & inhibitors*, metabolism
Oxidative Stress / drug effects
Pyrazines / metabolism, pharmacology*
Sterol Regulatory Element Binding Protein 1 / genetics, metabolism, pharmacology
|0/Anti-Inflammatory Agents; 0/Anticarcinogenic Agents; 0/Antioxidants; 0/Orphan Nuclear Receptors; 0/Pyrazines; 0/Sterol Regulatory Element Binding Protein 1; 0/liver X receptor; 6N510JUL1Y/oltipraz; EC 18.104.22.168/AMP-Activated Protein Kinases|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Melanoma ex blue nevus: two cases resembling large plaque-type blue nevus with subcutaneous cellular...
Next Document: Percutaneous cryoablation of renal masses: Washington University experience of treating 129 tumours.